MSD’s Keytruda and Padcev Combination Receives EC Approval
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.10 Articles
10 Articles
(Adnkronos) Msd announced today that the European Commission approved pembrolizumab in combination with enfortumab vedotin, as a neoadjuvant treatment and subsequently, after radical cystectomy, as adjuvant treatment in adults with muscle-invasive bladder cancer (Mibc) resectable. The approval informs a note
Giornale Radio
Msd announced today that the European Commission approved pembrolizumab in combination with enfortumab vedotin as neoadjuvant treatment and subsequently, after radical cystectomy, as adjuvant treatment in adults with muscle-invasive bladder cancer (Mibc) resectable. The approval - reports a note - "represents the first and only regimen with a PD-1 inhibitor plus a conjugate antibody-drug (Adc) available in the EU for patients with Mibc, regardle…
Merck (MRK) Wins EU Approval For Perioperative Bladder Cancer Treatment
Merck (NYSE:MRK) received European Commission approval for KEYTRUDA plus Padcev as perioperative therapy for muscle-invasive bladder cancer. The authorization covers adults with resectable muscle-invasive bladder cancer, regardless of their eligibility for cisplatin-based chemotherapy. The decision is based on positive Phase 3 clinical trial data supporting the KEYTRUDA and Padcev combination in this setting. The approval of KEYTRUDA plus Padcev…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
